Medtronic Named Among World’s Most Innovative Companies by MIT Technology Review

Company Recognized for Ground-Breaking Work in the Field of Deep Brain Stimulation

MINNEAPOLIS, March 4, 2010 – Medtronic, Inc. (NYSE: MDT) today announced that it has been selected as
one of Massachusetts Institute of Technology (MIT) Technology Review's 50
most innovative companies. Known as TR50, the first annual list includes
companies that Technology Review believes have demonstrated superiority [...]

Atacama Labs Enters Into Partnership With Excella Gmbh, Which is Part of Fareva Holding, a Top 10 Global Contract Manufacturer

A Finnish Company ATACAMA LABS OY and a German Based EXCELLA GmbH (Fareva Holding SA) Have Signed a Contract Manufacturing Agreement to Jointly Market and Sell PDG Granule and Tablet Manufacturing Services for the Pharmaceutical Industry

HELSINKI, Finland, March 4, 2010 – Atacama Labs Oy has developed an innovative oral drug delivery technology
(called 'pneumatic dry [...]

Genzyme Corporation’s Generous Benefaction to Enable the Creation of a Key Clinical Academic Post for Multiple Sclerosis, Neuroimmunological Diseases

Expands Commitment to University of Cambridge Community
CAMBRIDGE, England, March 4, 2010 – The University of Cambridge announced today that Genzyme Corporation, a
diversified, global biotechnology company with significant operations in
Cambridge and across the United Kingdom, has made a generous benefaction to
endow a key clinical academic post at the university dedicated to the
advancement of fundamental and [...]

First Breast Cancer Patients in Europe to be Treated With Revolutionary Therapy System

VEENENDAAL, The Netherlands, March 4, 2010 – Today the first patients in Europe are to receive treatment for breast
cancer using a revolutionary system called AccuBoost. The Italian hospital
where the patients are being treated is using the technology to pinpoint the
tumour bed and treat it whilst still protecting the patient's healthy
surrounding tissue and organs. This [...]

Isotechnika Pharma Receives National Research Council IRAP Funding for NICAM Program

EDMONTON, Canada, March 4, 2010 – Isotechnika Pharma Inc. (TSX: ISA) today announced that it has received
funding approval from the National Research Council's Industrial Research
Assistance Program (IRAP) for its Non-Immunosuppressive Cyclosporin Analog
Molecules (NICAM) program. The grant of CDN$237,069 will support the
development progress of the NICAM program which is part of an emerging
therapeutic field that [...]